Immune thrombocytopenic purpura: The treatment paradigm

European Journal of Haematology

Volumn 82, Issue SUPPL. 71, 2009, Pages 13-19

  Stasi, Roberto ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

Adults; Immune thrombocytopenic purpura; Paradigm; Treatment

Indexed keywords

AZATHIOPRINE; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LEVONORGESTREL; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; R 788; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; ROMIPLOSTIM; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL DECISION MAKING; MENORRHAGIA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; UNSPECIFIED SIDE EFFECT;

EID: 59549092757     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01208.x     Document Type: Review

References (35)

1. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004 79 : 504 22.
2. Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000 137 : 629 32.
3. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR, Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001 358 : 2122 5.
4. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995 98 : 436 42.
5. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001 97 : 2549 54.
6. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004 104 : 956 60.
7. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR, Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003 122 : 966 74.
8. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 88 : 3 40.
9. Provan D, Newland AC, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, May A, Murphy M, Ouwelhand W, Watson S. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003 120 : 574 96.
10. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008 99 : 4 13.
11. Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987 52 : 206 11.
12. The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997 126 : 319 26.
13. Culić S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003 120 : 909 10.
14. Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005 15 : 145 50.
15. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000 160 : 1630 8.
16. Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol 2008 83 : 93 6.
17. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003 349 : 831 6.
18. Mazzucconi MG, Fazi P, Bernasconi S, et al. Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007 109 : 1401 7.
19. Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomised trial comparing 0.5 and 1 g/kg B.W. Br J Haematol 1999 107 : 716 9.
20. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997 89 : 2689 700.
21. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001 112 : 1076 8.
22. Cooper NB, Woloski MR, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002 99 : 1922 7.
23. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004 104 : 2623 34.
24. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995 122 : 187 8.
25. Taragarona EM, Espert JJ, Balague C, Sugrañes G, Ayuso C, Lomeña F, Bosch F, Trias M. Residual splenic function after laparoscopic splenectomy: a clinical concern. Arch Surg 1998 133 : 56 60.
26. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2008 Oct 22 (Epub ahead of print).
27. Laufer D, Ardekian L. Oral Surgery: transexamic acid and blood loss. Br Dent J 1999 186 : 624.
28. Endo Y, Nishimura S, Miura A. Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura. JAMA 1988 259 : 3561 2.
29. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 : 25 33.
30. Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, Tanaka S, Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004 103 : 1229 36.
31. US National Institutes of Health : Rigel Pharmaceuticals. Pilot Study of R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) http://www.clinicaltrials.gov/ct/show/NCT00706342 (accessed on 9 January 2009).
32. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007 14 : 642 6.
33. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008 371 : 395 403.
34. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 357 : 2237 47.
35. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003 101 : 71 7.